vs
Alkermes plc.（ALKS）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Alkermes plc.的季度营收约是Rocket Lab Corp的1.9倍（$384.5M vs $200.3M），Alkermes plc.净利率更高（12.8% vs -22.5%，领先35.3%），Rocket Lab Corp同比增速更快（63.5% vs -10.6%），过去两年Rocket Lab Corp的营收复合增速更高（37.3% vs 4.8%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
ALKS vs RKLB — 直观对比
营收规模更大
ALKS
是对方的1.9倍
$200.3M
营收增速更快
RKLB
高出74.0%
-10.6%
净利率更高
ALKS
高出35.3%
-22.5%
两年增速更快
RKLB
近两年复合增速
4.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $200.3M |
| 净利润 | $49.3M | $-45.0M |
| 毛利率 | 88.0% | 38.2% |
| 营业利润率 | 15.1% | 33.9% |
| 净利率 | 12.8% | -22.5% |
| 营收同比 | -10.6% | 63.5% |
| 净利润同比 | -66.3% | — |
| 每股收益（稀释后） | $0.29 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSRKLB
| Q1 26 | — | $200.3M | ||
| Q4 25 | $384.5M | $179.7M | ||
| Q3 25 | $394.2M | $155.1M | ||
| Q2 25 | $390.7M | $144.5M | ||
| Q1 25 | $306.5M | $122.6M | ||
| Q4 24 | $430.0M | $132.4M | ||
| Q3 24 | $378.1M | $104.8M | ||
| Q2 24 | $399.1M | $106.3M |
净利润ALKSRKLB
| Q1 26 | — | $-45.0M | ||
| Q4 25 | $49.3M | $-52.9M | ||
| Q3 25 | $82.8M | $-18.3M | ||
| Q2 25 | $87.1M | $-66.4M | ||
| Q1 25 | $22.5M | $-60.6M | ||
| Q4 24 | $146.5M | $-52.3M | ||
| Q3 24 | $92.4M | $-51.9M | ||
| Q2 24 | $91.4M | $-41.6M |
毛利率ALKSRKLB
| Q1 26 | — | 38.2% | ||
| Q4 25 | 88.0% | 38.0% | ||
| Q3 25 | 86.9% | 37.0% | ||
| Q2 25 | 87.3% | 32.1% | ||
| Q1 25 | 83.9% | 28.8% | ||
| Q4 24 | 85.6% | 27.8% | ||
| Q3 24 | 83.3% | 26.7% | ||
| Q2 24 | 84.6% | 25.6% |
营业利润率ALKSRKLB
| Q1 26 | — | 33.9% | ||
| Q4 25 | 15.1% | -28.4% | ||
| Q3 25 | 22.6% | -38.0% | ||
| Q2 25 | 23.8% | -41.3% | ||
| Q1 25 | 4.5% | -48.3% | ||
| Q4 24 | 37.8% | -38.9% | ||
| Q3 24 | 27.7% | -49.5% | ||
| Q2 24 | 27.5% | -40.7% |
净利率ALKSRKLB
| Q1 26 | — | -22.5% | ||
| Q4 25 | 12.8% | -29.5% | ||
| Q3 25 | 21.0% | -11.8% | ||
| Q2 25 | 22.3% | -46.0% | ||
| Q1 25 | 7.3% | -49.5% | ||
| Q4 24 | 34.1% | -39.5% | ||
| Q3 24 | 24.4% | -49.6% | ||
| Q2 24 | 22.9% | -39.2% |
每股收益（稀释后）ALKSRKLB
| Q1 26 | — | — | ||
| Q4 25 | $0.29 | $-0.09 | ||
| Q3 25 | $0.49 | $-0.03 | ||
| Q2 25 | $0.52 | $-0.13 | ||
| Q1 25 | $0.13 | $-0.12 | ||
| Q4 24 | $0.88 | $-0.11 | ||
| Q3 24 | $0.55 | $-0.10 | ||
| Q2 24 | $0.53 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $1.2B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $2.3B |
| 总资产 | $2.5B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSRKLB
| Q1 26 | — | $1.2B | ||
| Q4 25 | $388.6M | $1.0B | ||
| Q3 25 | $616.4M | $976.7M | ||
| Q2 25 | $521.2M | $688.1M | ||
| Q1 25 | $399.8M | $428.4M | ||
| Q4 24 | $291.1M | $419.0M | ||
| Q3 24 | $396.3M | $442.4M | ||
| Q2 24 | $535.1M | $496.8M |
总债务ALKSRKLB
| Q1 26 | — | — | ||
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M |
股东权益ALKSRKLB
| Q1 26 | — | $2.3B | ||
| Q4 25 | $1.8B | $1.7B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $688.5M | ||
| Q1 25 | $1.5B | $431.3M | ||
| Q4 24 | $1.5B | $382.5M | ||
| Q3 24 | $1.3B | $419.8M | ||
| Q2 24 | $1.3B | $455.2M |
总资产ALKSRKLB
| Q1 26 | — | $2.8B | ||
| Q4 25 | $2.5B | $2.3B | ||
| Q3 25 | $2.3B | $2.2B | ||
| Q2 25 | $2.3B | $1.6B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.2B | $1.2B | ||
| Q2 24 | $2.2B | $1.2B |
负债/权益比ALKSRKLB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $-50.3M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | — |
| 自由现金流率自由现金流/营收 | 44.2% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 3.45× | — |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
经营现金流ALKSRKLB
| Q1 26 | — | $-50.3M | ||
| Q4 25 | $170.1M | $-64.5M | ||
| Q3 25 | $101.7M | $-23.5M | ||
| Q2 25 | $150.2M | $-23.2M | ||
| Q1 25 | $98.8M | $-54.2M | ||
| Q4 24 | $190.4M | $-2.4M | ||
| Q3 24 | $81.6M | $-30.9M | ||
| Q2 24 | $146.0M | $-13.0M |
自由现金流ALKSRKLB
| Q1 26 | — | — | ||
| Q4 25 | $170.0M | $-114.2M | ||
| Q3 25 | $84.4M | $-69.4M | ||
| Q2 25 | $137.2M | $-55.3M | ||
| Q1 25 | $88.7M | $-82.9M | ||
| Q4 24 | $180.6M | $-23.9M | ||
| Q3 24 | $73.3M | $-41.9M | ||
| Q2 24 | $138.9M | $-28.3M |
自由现金流率ALKSRKLB
| Q1 26 | — | — | ||
| Q4 25 | 44.2% | -63.6% | ||
| Q3 25 | 21.4% | -44.8% | ||
| Q2 25 | 35.1% | -38.3% | ||
| Q1 25 | 28.9% | -67.6% | ||
| Q4 24 | 42.0% | -18.1% | ||
| Q3 24 | 19.4% | -40.0% | ||
| Q2 24 | 34.8% | -26.7% |
资本支出强度ALKSRKLB
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 27.6% | ||
| Q3 25 | 4.4% | 29.6% | ||
| Q2 25 | 3.3% | 22.2% | ||
| Q1 25 | 3.3% | 23.4% | ||
| Q4 24 | 2.3% | 16.3% | ||
| Q3 24 | 2.2% | 10.5% | ||
| Q2 24 | 1.8% | 14.4% |
现金转化率ALKSRKLB
| Q1 26 | — | — | ||
| Q4 25 | 3.45× | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RKLB
| Product revenues | $127.5M | 64% |
| Service revenues | $72.9M | 36% |
